17:37 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Ascletis' NDA for second HCV therapy accepted in China, company begins trading in Hong Kong

Ascletis Pharma Inc. (HKSE:1672) said China's State Drug Administration accepted its NDA for HCV therapy ravidasvir, a second-generation HCV NS5A protein inhibitor. In June, Ascletis launched HCV drug Ganovo danoprevir in China. Ascletis has rights to...
22:18 , Jul 17, 2018 |  BC Extra  |  Financial News

CanSino latest to file for HKEX IPO

Vaccines company CanSino Biologics Inc. (Tianjin, China) on Tuesday proposed to list on Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by Morgan Stanley and CLSA. The news comes as multiple media...
22:02 , Jul 17, 2018 |  BC Extra  |  Financial News

CanSino latest to file for HKEX IPO

Vaccines company CanSino Biologics Inc. (Tianjin, China) on Tuesday proposed to list on Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by Morgan Stanley and CLSA. The news comes as multiple media...
18:19 , Jun 29, 2018 |  BC Week In Review  |  Company News

Ascletis, CR Pharmaceutical partner to distribute HCV drug in Beijing

Ascletis Pharma Inc. (Hangzhou, China) partnered with the CR Pharmaceutical Commercial Group Co. Ltd. subsidiary of China Resources Pharmaceutical Group Ltd. (Beijing, China) to develop distribution networks and end-user services in Beijing for the launch...
20:22 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Chinese approval for Ascletis' HCV drug

Ascletis Pharmaceuticals Co. Ltd. (Hangzhou, China) said China's State Drug Administration approved an NDA for Ganovo danoprevir to treat HCV. The company intends to launch the product next quarter, according to its website. Ascletis said...
21:07 , Jun 13, 2018 |  BC Extra  |  Company News

Chinese approval for Ascletis' HCV drug

Ascletis Pharmaceuticals Co. Ltd. (Hangzhou, China) said China's State Drug Administration approved an NDA for Ganovo danoprevir to treat HCV. The company intends to launch the product next quarter, according to its website. Ascletis said...
18:05 , May 25, 2018 |  BioCentury  |  Finance

HKEX’s on-demand experts

The Hong Kong stock exchange is well aware its investor base is new to the high-risk, high-reward nature of its newly hatched biotech chapter and has no qualms about admitting its own lack of expertise....
18:29 , May 11, 2018 |  BC Week In Review  |  Financial News

Ascletis first to apply for HKEX biotech chapter

Ascletis Pharma Inc. (Hangzhou, China) plans to list on Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by Morgan Stanley, Goldman Sachs and China Merchants, according to a regulatory filing on May...
19:44 , May 7, 2018 |  BC Extra  |  Financial News

Ascletis first to apply for HKEX biotech chapter

Ascletis Pharma Inc. (Hangzhou, China) plans to list on Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by Morgan Stanley, Goldman Sachs and China Merchants Securities, according to a regulatory filing. The company...
21:43 , Oct 27, 2017 |  BC Week In Review  |  Company News

Arcturus, JNJ to develop nucleic acids to treat HBV

Arcturus Therapeutics Inc. (San Diego, Calif.) and the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to develop and commercialize nucleic acid-based compounds to treat HBV. The companies will use Arcturus' unlocked nucleomonomer...